<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="752">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759589</url>
  </required_header>
  <id_info>
    <org_study_id>Inonu University Anesthesia</org_study_id>
    <secondary_id>Inonu University</secondary_id>
    <nct_id>NCT01759589</nct_id>
  </id_info>
  <brief_title>Three Anaesthesic Method in Electroconvulsive Theraphy</brief_title>
  <official_title>Sevoflurane Alone and Propofol With or Without Remifentanil in Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of three different anesthetic regimens (propofol,
      remifentanil-propofol and sevoflurane in ECT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effectiveness of three different anesthetic
      regimens (propofol, remifentanil-propofol and sevoflurane) with respect to seizure duration,
      postictal suppression index, early and midictal amplitude, hemodynamic variables and
      recovery profiles in ECT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Seizure duration</measure>
    <time_frame>The patients were observed about seizure up to ten minutes after electrical stimulation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After anesthesia induction patients were administered electrical stimulation and seizure duration were measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postictal suppression index</measure>
    <time_frame>completing seizure in one hour</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After anesthesia induction, patients were administered electrical stimulation. Then, postictal suppression index, a parameter that shows seizure quality, was determined from seizure records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery parameters (spontaneous breathing, eye opening, and obeying of verbal commands)</measure>
    <time_frame>after seizure in one hour in operation room.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The time from the end of succinylcholine administration to the recovery of spontaneous breathing, eye opening, and obeying of verbal commands were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic variables</measure>
    <time_frame>Before administration of the study medications (t0), and at 1 (t1), 3 (t2), and 10 (t3) minutes after the seizure ended.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>During perioperative period:
Before administration of the study medications (t0), and at 1 (t1), 3 (t2), and 10 (t3) minutes after the seizure ended.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>propofol (Group P)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil and propofol (Group R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane (Group S)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>1 mg/kg propofol IV (over 15 sec) during anesthesia induction</description>
    <arm_group_label>propofol (Group P)</arm_group_label>
    <other_name>Intravenous anesthetic agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil and propofol</intervention_name>
    <description>1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction</description>
    <arm_group_label>remifentanil and propofol (Group R)</arm_group_label>
    <other_name>Opioid and intravenous anesthetic agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered</description>
    <arm_group_label>sevoflurane (Group S)</arm_group_label>
    <other_name>Volatil anesthetic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upremedicated ASA I-II (American Society of Anesthesiologists's physical status)
             patients,

          -  Patients scheduled for six ECT sessions for a variety of psychiatric conditions
             (major depression, schizophrenia)

        Exclusion Criteria:

          -  Involuntary patient status

          -  Patients with known or self-declared needle or mask phobia

          -  Pregnancy

          -  Asthma

          -  Cerebrovascular disease,

          -  History of myocardial infarction in the previous 6 months,

          -  Atrial fibrillation or flutter,heart block,

          -  A known or family history of reactions to the study drugs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zekine Begec</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <zip>44315</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Toprak HI, Gedik E, Begeç Z, Oztürk E, Kaya B, Ersoy MO. Sevoflurane as an alternative anaesthetic for electroconvulsive therapy. J ECT. 2005 Jun;21(2):108-10.</citation>
    <PMID>15905753</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 31, 2012</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Zekine Begec</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>electroconvulsive therapy,sevoflurane,propofol,remifentanil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
